Algerian Pharma & Healthcare: 5 Things to Know
With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the…
Groupe Saidal is the largest pharmaceutical company in Algeria and one of the largest in Africa.
Saidal is a joint-stock company with a capital of 2,500,000 dinars in Algeria. 80 percent of Saidal Group’s capital is held by the State, and the remaining 20 percent was sold through the stock market in 1999 to institutional investors and individuals.
Organised into an industrial group, Saidal’s mission is to develop, produce and market pharmaceutical products for human use.
The Saidal Group’s strategic objective is to consolidate its leading position in the production of generic medicines and to contribute, in doing so, to the execution of the national drug policy implemented by the public authorities.
With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the…
Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that…
A roundup of the latest news from pharma in the Middle East and Africa including China’s announcement that it will be prioritising Africa for access to its COVID-19 vaccine, UAE…
In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for…
Below we present recent news from Algeria’s pharmaceutical industry, including the creation of a dedicated Ministry to boost the sector, changes to the advertising rules for dietary supplements, and local…
Yacine Sellam examines how pharmacists in Algeria can follow the lead of their US counterparts and play a greater role in patients’ diabetes management. Noncommunicable diseases are a growing…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, looks at how European countries such as France and Belgium have countered medicine supply shortages and how Algeria…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.…
The Middle East and North Africa (MENA) region’s pharmaceutical market is projected to reach a value of around USD 60 billion by 2025 according to reporting from TradeArabia. The most…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken…
Adlane Soudani, general manager of Ipsen’s Algerian affiliate, lifts the lid on Ipsen’s ambitions for the local market, and the company’s parallel strategies to ramp up local production while simultaneously…
Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we…
See our Cookie Privacy Policy Here
